Rigel Pharmaceuticals, Inc

(NASDAQ:RIGL)

Latest On Rigel Pharmaceuticals, Inc (RIGL):

Date/Time Type Description Signal Details
2023-05-26 15:54 ESTNewsRigel Pharmaceuticals Shows Promise With Q1 Earnings: Tavalisse And Rezlidhia Drive GrowthN/A
2023-05-03 02:14 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.02, revenue of $26.07M beats by $2MN/A
2023-05-03 02:13 ESTNewsRigel Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-03 02:13 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q1 2023 Earnings Call TranscriptN/A
2023-05-02 01:42 ESTNewsRigel Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-27 09:21 ESTNewsRigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For ProfitabilityN/A
2023-04-04 02:31 ESTNewsRigel Pharma begun at neutral at Piper Sandler on value creation potentialN/A
2023-03-09 06:02 ESTNewsRigel Pharmaceuticals' Challenges Continue To Outweigh Potential UpsideN/A
2023-03-08 00:02 ESTNewsRigel Pharma, with beats on quarterly top and bottom lines, surges 19%N/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals GAAP EPS of $0.34 beats by $0.80, revenue of $120.24M beats by $27.04MN/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call TranscriptN/A
2023-03-06 18:38 ESTNewsRigel Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-28 01:25 ESTNewsRigel Pharmaceuticals (RIGL) Investor Presentation - SlideshowN/A
2023-01-09 20:04 ESTNewsRigel Pharma rises as preliminary Q4 revenue above estimatesN/A
2022-12-31 03:48 ESTNewsRigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023N/A
2022-12-22 20:32 ESTNewsRigel launches leukemia therapy in U.S.N/A
2022-12-15 15:09 ESTNewsRigel extends gains as dosing starts in early-stage trial for blood cancer therapyN/A
2022-12-03 04:05 ESTNewsRigel upgraded at Citi on bullish outlook for new leukemia drugN/A
2022-12-02 10:34 ESTNewsRigel stock soars 40% on FDA approval of blood cancer drug RezlidhiaN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.11 beats by $0.03, revenue of $22.4M misses by $0.21MN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Call TranscriptN/A
2022-11-02 22:35 ESTNewsRigel Pharma gains as analysts play down setback for COVID-19 therapyN/A
2022-10-31 23:15 ESTNewsRigel Pharmaceuticals Provides An Opportunity For Investors Or An AcquirerN/A
2022-10-11 06:01 ESTNewsRigel cutting 16% of workforce after declining to file sNDA for fostamatinibN/A
2022-08-18 23:47 ESTNewsRigel Pharma adds ~7% to reach over two month highN/A
2022-08-04 01:22 ESTNewsRigel rises 17% on strong Q2 resultN/A
2022-08-03 10:19 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-03 10:19 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-02 20:22 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.04, revenue of $29.82M beats by $6.17MN/A
2022-08-02 05:27 ESTNewsRigel Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-10 02:16 ESTNewsRigel Pharma downgraded at several street firms following anemia study failureN/A
2022-06-09 00:09 ESTNewsRigel stock crashes 48% as fostamatinib fails phase 3 anemia studyN/A
2022-06-09 00:08 ESTNewsRigel cut to Neutral at Cantor Fitzgerald after trial miss wipes out half of stock valueN/A
2022-05-31 10:56 ESTNewsRigel Pharmaceuticals: A Status CheckN/A
2022-05-04 11:44 ESTNewsRigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-03 19:55 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.16 misses by $0.02, revenue of $16.74M misses by $0.8MN/A
2022-05-03 19:54 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-03 01:40 ESTNewsRigel Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-08 20:19 ESTNewsRigel Pharmaceuticals grants stock options to employeesN/A
2022-03-22 02:13 ESTNewsRigel Pharmaceuticals: Why The Stock Is On A RunN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.13 in-line, revenue of $20.41M misses by $0.79MN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-02-28 17:57 ESTNewsRigel Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-01 13:56 ESTNewsRigel Pharmaceuticals: A Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety NetN/A
2022-01-11 00:53 ESTNewsRigel down as it expects slight decrease in products sales in Q4 compared to prior yearN/A
2021-12-22 03:23 ESTNewsRigel Pharma says its trial for bleeding disorder therapy met main goal in JapanN/A
2021-11-30 10:44 ESTNewsRigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects AliveN/A

About Rigel Pharmaceuticals, Inc (RIGL):

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

See Advanced Chart

General

  • Name Rigel Pharmaceuticals, Inc
  • Symbol RIGL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 169
  • Last Split Factor1:9
  • Last Split Date2003-06-25
  • Fiscal Year EndDecember
  • IPO Date2000-11-29
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.rigel.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 6.34
  • Price/Book (Most Recent Quarter) 20.39
  • Enterprise Value Revenue 6.22
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.02
  • Next Year EPS Estimate -$0.20
  • Next Quarter EPS Estimate -$0.03
  • Profit Margin -27%
  • Operating Margin -27%
  • Return on Assets -14%
  • Return on Equity -68%
  • Revenue 108.62 million
  • Earnings Per Share -$0.35
  • Revenue Per Share $0.64
  • Gross Profit 47.63 million
  • Quarterly Earnings Growth 19.8%
View More

Highlights

  • Market Capitalization 689.52 million
  • EBITDA -60896000
  • PE Ratio -16.62
  • PEG Ratio -0.1
  • Analyst Target Price $8.5
  • Book Value Per Share $0.20
View More

Share Statistics

  • Shares Outstanding 170.04 million
  • Shares Float 169.52 million
  • % Held by Insiders 31%
  • % Held by Institutions 85.26%
  • Shares Short 16.81 million
  • Shares Short Prior Month 19.36 million
  • Short Ratio 3.15
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.45
  • 52 Week High $5.5
  • 52 Week Low $1.26
  • 50 Day Moving Average 4.2
  • 200 Day Moving Average 3.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Rigel Pharmaceuticals, Inc (RIGL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Rigel Pharmaceuticals, Inc (RIGL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$18.45 million-$0.11-$0.113.51%
2020-09-302020-11-05$18.39 million-$0.08-$0.1234.05%
2020-06-302020-08-04$16.02 million-$0.10-$0.1426.09%
2020-03-312020-05-05$55.76 million$0.13$0.13-1.59%
2019-12-312020-02-27$15.4 million-$0.10-$0.1217.56%
2019-09-302019-11-05$20.86 million-$0.07-$0.1032.69%
2019-06-302019-08-06$10.41 million-$0.12-$0.1412.22%
2019-03-312019-05-07$12.62 million-$0.11-$0.1315.38%
2018-12-312019-02-28$37.86 million$0.02$0.03-41.35%
2018-09-302018-11-06$4.87 million-$0.14-$0.157.83%
2018-06-302018-08-08$1.79 million-$0.16-$0.16-0.19%
2018-03-312018-05-01$N/A-$0.17-$0.183.41%
2017-12-312018-03-06$3.58 million-$0.18-$0.13-35.03%
2017-09-302017-11-07$900000-$0.14-$0.158.32%
2017-06-302017-08-01$-3584000-$0.16-$0.14-12.76%
2017-03-312017-05-02$3.58 million-$0.13-$0.12-5.18%
2016-12-312017-03-07$3 million-$0.16-$0.175.33%
2016-09-302016-11-01$3.76 million-$0.24-$0.23-3.99%
2016-06-302016-08-02$8.59 million-$0.15-$0.2026.33%
2016-03-312016-05-03$5.03 million-$0.19-$0.219.18%
2015-12-312016-03-08$8.54 million-$0.14-$0.14-3.47%
2015-09-302015-11-03$13 million-$0.08-$0.1752.94%
2015-06-302015-08-04$5.18 million-$0.16-$0.2227.27%
2015-03-312015-05-07$2.18 million-$0.21-$0.18-16.67%
2014-12-312015-03-03$8.25 million-$0.15-$0.2642.31%
2014-09-302014-11-04$N/A-$0.24-$0.2711.11%
2014-06-302014-08-05$N/A-$0.29-$0.25-16%
2014-03-312014-05-07$N/A-$0.25-$0.250%
2013-12-312014-03-04$5.75 million-$0.19-$0.2524%
2013-09-302013-11-05$-1400000-$0.25-$0.2913.79%
2013-06-302013-08-06$1.4 million-$0.26-$0.3013.33%
2013-03-312013-05-07$N/A-$0.29-$0.303.33%
2012-12-312013-03-05$2.25 million-$0.30-$0.326.25%
2012-09-302012-11-06$-1500000-$0.36-$0.372.7%
2012-06-302012-08-07$1.5 million-$0.35-$0.350%
2012-03-312012-05-01$750000-$0.32-$0.31-3.23%
2011-12-312012-03-06$395000-$0.36-$0.28-28.57%
2011-09-302011-11-01$4.36 million-$0.25-$0.3016.67%
2011-06-302011-08-02$395000-$0.37-$0.382.63%
2011-03-312011-05-03$N/A-$0.40-$0.36-11.11%
2010-12-312011-03-01$52.72 million-$0.33-$0.368.33%
2010-09-302010-11-02$72.28 million$0.96$0.6254.84%
2010-06-302010-08-03$49.46 million$0.51$0.478.51%
2010-03-312010-05-04$3.26 million-$0.43$0.11-490.91%
2009-12-312010-03-02$750000-$0.48-$0.45-6.67%
2009-09-302009-11-03$N/A-$0.70-$0.58-20.69%
2009-06-302009-08-04$N/A-$0.81-$0.810%
2009-03-312009-05-05$N/A-$0.82-$0.9917.17%
2008-12-312009-02-24$N/A-$0.91-$0.976.19%
2008-09-302008-11-03$N/A-$1.03-$0.87-18.39%
2008-06-302008-08-05$N/A-$0.93-$0.69-34.78%
2008-03-312008-05-06$N/A-$0.79-$0.62-27.42%
2007-12-312008-02-12$8 million-$0.61-$0.43-41.86%
2007-09-302007-11-06$-1956000-$0.61-$0.57-7.02%
2007-06-302007-08-07$1.96 million-$0.68-$0.63-7.94%
2007-03-312007-05-10$2.64 million-$0.68-$0.67-1.49%
2006-12-312007-02-06$3.13 million-$0.62-$0.643.13%
2006-09-302006-11-07$6.13 million-$0.46-$0.472.13%
2006-06-302006-08-02$14.32 million-$0.09-$0.5683.93%
2006-03-312006-05-02$9.9 million-$0.34-$0.32-6.25%
2005-12-312006-02-07$6.02 million-$0.36-$0.4316.28%
2005-09-302005-11-08$3.28 million-$0.56-$0.618.2%
2005-06-302005-08-03$4.61 million-$0.62-$0.7112.68%
2005-03-312005-05-03$2.62 million-$0.57-$0.48-18.75%
2004-12-312005-02-08$1.1 million-$0.75-$0.69-8.7%
2004-09-302004-11-05$659000-$0.88-$0.71-23.94%
2004-06-302004-08-03$1.49 million-$0.68-$0.748.11%
2004-03-312004-05-04$1.49 million-$0.81-$0.78-3.85%
2003-12-312004-02-03$2.11 million-$0.80-$0.71-12.68%
2003-09-302003-11-05$2.1 million-$0.78
2003-06-302003-08-05$2.35 million-$1.90
2003-03-312003-05-06$4.5 million-$1.53
2002-12-312003-02-05$3.7 million-$1.62-$2.1625%
2002-09-302002-11-04$3.65 million-$1.98-$1.80-10%
2002-06-302002-08-06$4.34 million-$2.07-$1.35-53.33%
2002-03-312002-05-07$4.1 million-$1.71-$1.53-11.76%
2001-12-312002-02-05$4.78 million-$1.44-$1.8421.74%
2001-09-302001-11-07$4.21 million-$1.53-$1.530%
2001-06-302001-08-08$3.12 million-$1.80-$0.99-81.82%
2001-03-312001-05-08$3.19 million-$0.99-$1.4431.25%
2000-12-312001-02-07$3.21 million-$3.24-$2.34-38.46%

Rigel Pharmaceuticals, Inc (RIGL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Rigel Pharmaceuticals, Inc (RIGL) Chart:

Rigel Pharmaceuticals, Inc (RIGL) News:

Below you will find a list of latest news for Rigel Pharmaceuticals, Inc (RIGL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Rigel Pharmaceuticals, Inc (RIGL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-01-162524CALL0 27113.21TRUE00
2026-01-163012CALL0 1111TRUE00
2026-01-16358.2CALL0 360.74TRUE00
2026-01-16370CALL0 071.72TRUE00
2026-01-163813.37CALL0 1167.19TRUE00
2026-01-16390CALL0 067.42TRUE00
2026-01-16404.12CALL1 71269.55TRUE4.120
2026-01-16412.8CALL0 1862.15TRUE00
2026-01-16423.78CALL0 662.84TRUE00
2026-01-16432.72CALL0 2169.18FALSE00
2026-01-16441.4CALL0 13147.75FALSE00
2026-01-16451.25CALL0 60158.71FALSE00
2026-01-16462CALL0 5168.92FALSE00
2026-01-16472.1CALL0 14156.06FALSE00
2026-01-16481.67CALL0 19187.57FALSE00
2026-01-16490.9CALL0 15119.59FALSE00
2026-01-16500.8CALL0 140204.36FALSE00
2026-01-16550.35CALL0 7240.47FALSE00
2026-01-16600.07CALL0 5234.71FALSE00
2026-01-16651.04CALL0 12250.45FALSE00
2026-01-16700.03CALL0 6103.87FALSE00
2026-01-16250.05PUT15 7121.38FALSE0.050
2026-01-16300PUT0 0146.09FALSE00
2026-01-16350.25PUT0 5296.95FALSE00
2026-01-16370.33PUT0 2152.69FALSE00
2026-01-16380.6PUT0 5208.56FALSE00
2026-01-16391.25PUT0 6193.56FALSE00
2026-01-16401.13PUT0 12178.6FALSE00
2026-01-16411.1PUT1 1654.25FALSE1.10
2026-01-16422.85PUT0 4148.4FALSE00
2026-01-16432.2PUT0 367.61TRUE00
2026-01-16443PUT0 457.24TRUE00
2026-01-16454.37PUT0 260.4TRUE00
2026-01-16464PUT0 1061.12TRUE00
2026-01-16474.41PUT0 363.46TRUE00
2026-01-16486.56PUT0 252.13TRUE00
2026-01-16490PUT0 053.08TRUE00
2026-01-16506.62PUT0 042.5TRUE00
2026-01-16550PUT0 00TRUE00
2026-01-16600PUT0 00TRUE00
2026-01-16650PUT0 00TRUE00
2026-01-16700PUT0 00TRUE00
2026-02-203013.9CALL0 179.19TRUE00
2026-02-20340CALL0 067.39TRUE00
2026-02-203510CALL0 166.65TRUE00
2026-02-20360CALL0 062.99TRUE00
2026-02-20370CALL0 061.23TRUE00
2026-02-20380CALL0 061.89TRUE00
2026-02-20390CALL0 062.61TRUE00
2026-02-20405.52CALL1 062.03TRUE5.520
2026-02-20410CALL0 063.86TRUE00
2026-02-20420CALL0 060.03TRUE00
2026-02-20430CALL0 059.64FALSE00
2026-02-20440CALL0 045.71FALSE00
2026-02-20452.75CALL0 1254.22FALSE00
2026-02-20463.7CALL0 844.52FALSE00
2026-02-20472CALL0 152.41FALSE00
2026-02-20482.9CALL0 20467.52FALSE00
2026-02-20492.1CALL0 191.61FALSE00
2026-02-20501.85CALL0 294.52FALSE00
2026-02-20550CALL0 087.22FALSE00
2026-02-20600CALL0 079.76FALSE00
2026-02-20300.81PUT0 5102.21FALSE00
2026-02-20340.85PUT0 1283.85FALSE00
2026-02-20350PUT0 072.8FALSE00
2026-02-20360PUT0 097.56FALSE00
2026-02-20371.35PUT0 272.78FALSE00
2026-02-20381.7PUT0 451.31FALSE00
2026-02-20391.9PUT1 558.48FALSE1.90
2026-02-20402.05PUT3 454.36FALSE2.050
2026-02-20412.6PUT1 556.5FALSE2.60
2026-02-20420PUT0 043.29FALSE00
2026-02-20430PUT0 040.13TRUE00
2026-02-20440PUT0 043.53TRUE00
2026-02-20450PUT0 059.95TRUE00
2026-02-20460PUT0 061.3TRUE00
2026-02-20470PUT0 053.49TRUE00
2026-02-20480PUT0 056.52TRUE00
2026-02-20490PUT0 053.79TRUE00
2026-02-20500PUT0 054.01TRUE00
2026-02-20550PUT0 050.21TRUE00
2026-02-20600PUT0 055.1TRUE00
2026-03-2050CALL0 0260.19TRUE00
2026-03-201034CALL0 10183.39TRUE00
2026-03-20110CALL0 0170.88TRUE00
2026-03-20120CALL0 0159.58TRUE00
2026-03-201324.4CALL0 1149.28TRUE00
2026-03-20140CALL0 0139.81TRUE00
2026-03-201530CALL0 4131.06TRUE00
2026-03-20160CALL0 0122.92TRUE00
2026-03-20170CALL0 0115.32TRUE00
2026-03-20180CALL0 0108.18TRUE00
2026-03-201913CALL0 0101.46TRUE00
2026-03-202022.8CALL0 7395.1TRUE00
2026-03-20219.8CALL0 193TRUE00
2026-03-202210.1CALL0 487.16TRUE00
2026-03-20230CALL0 073.56TRUE00
2026-03-20247CALL0 187.55TRUE00
2026-03-202517.5CALL0 4286.52TRUE00
2026-03-20260CALL0 084.99TRUE00
2026-03-202720.09CALL0 1775.85TRUE00
2026-03-202817.9CALL0 577.76TRUE00
2026-03-20294.91CALL0 381.29TRUE00
2026-03-203014CALL0 23873.26TRUE00
2026-03-203113.7CALL0 2573.16TRUE00
2026-03-203220.21CALL0 5873.57TRUE00
2026-03-203319.08CALL0 672.35TRUE00
2026-03-203412.56CALL0 372.63TRUE00
2026-03-203510.03CALL3 17469.41TRUE0.180.02
2026-03-203611.6CALL0 1069.19TRUE00
2026-03-203713.4CALL0 1868.19TRUE00
2026-03-20387.6CALL0 6666.09TRUE00
2026-03-20397.61CALL0 1267.25TRUE00
2026-03-20406.95CALL7 14468.57TRUE0.240.04
2026-03-20419.3CALL0 768.73TRUE00
2026-03-20426CALL0 8865.9TRUE00
2026-03-20435.1CALL0 1353.24FALSE00
2026-03-20445.2CALL0 2069.46FALSE00
2026-03-20454.99CALL0 11765.01FALSE00
2026-03-20464.45CALL0 657.69FALSE00
2026-03-20473.1CALL0 11363.27FALSE00
2026-03-20503.06CALL0 3653.37FALSE00
2026-03-20551.3CALL0 3361.54FALSE00
2026-03-20601.1CALL0 6261.17FALSE00
2026-03-20650.82CALL0 1485FALSE00
2026-03-20700.8CALL0 193.15FALSE00
2026-03-2050.67PUT0 31070.2FALSE00
2026-03-20100PUT0 0462.52FALSE00
2026-03-20111.05PUT0 1427.7FALSE00
2026-03-20121.25PUT0 1398.18FALSE00
2026-03-20130PUT0 0372.6FALSE00
2026-03-20140.2PUT0 9287.81FALSE00
2026-03-20150PUT0 0279.06FALSE00
2026-03-20160PUT0 0311.61FALSE00
2026-03-20170PUT0 0144.07FALSE00
2026-03-20180.85PUT0 2150.83FALSE00
2026-03-20190PUT0 0131.38FALSE00
2026-03-20200.35PUT0 2135.18FALSE00
2026-03-20212.4PUT0 1125.99FALSE00
2026-03-20220.18PUT0 7111.16FALSE00
2026-03-20232.7PUT0 1105.03FALSE00
2026-03-20243.3PUT0 699.17FALSE00
2026-03-20253.1PUT0 9115.93FALSE00
2026-03-20263.8PUT0 193.21FALSE00
2026-03-20274.3PUT0 1112.29FALSE00
2026-03-20282.8PUT0 11107.16FALSE00
2026-03-20294.85PUT0 389.23FALSE00
2026-03-20301.23PUT0 4588.38FALSE00
2026-03-20315.3PUT0 10084.99FALSE00
2026-03-20321.5PUT0 1282.53FALSE00
2026-03-20331.35PUT0 484.56FALSE00
2026-03-20341.55PUT0 380.61FALSE00
2026-03-20351.8PUT0 478.29FALSE00
2026-03-20362.1PUT0 878.13FALSE00
2026-03-20372.4PUT0 494.71FALSE00
2026-03-20383.2PUT0 655.15FALSE00
2026-03-20393.8PUT0 955.52FALSE00
2026-03-20404.4PUT0 1063.53FALSE00
2026-03-20412.95PUT12 065.23FALSE2.950
2026-03-20420PUT0 065.13FALSE00
2026-03-204310.19PUT0 861.14TRUE00
2026-03-20440PUT0 053.68TRUE00
2026-03-204510.5PUT0 070.09TRUE00
2026-03-204611.89PUT0 1167.24TRUE00
2026-03-20470PUT0 063.4TRUE00
2026-03-20500PUT0 061.81TRUE00
2026-03-205513.06PUT3 056.38TRUE13.060
2026-03-20600PUT0 058.16TRUE00
2026-03-20650PUT0 063.36TRUE00
2026-03-20700PUT0 00TRUE00
2026-06-181527.35CALL0 1484.06TRUE00
2026-06-18190CALL0 087.32TRUE00
2026-06-18200CALL0 082.05TRUE00
2026-06-182116.6CALL0 186.22TRUE00
2026-06-182215.8CALL0 176.96TRUE00
2026-06-182323.01CALL0 476.37TRUE00
2026-06-182414.2CALL0 176.59TRUE00
2026-06-182522CALL5 2678.37TRUE30.16
2026-06-182613.6CALL0 673.77TRUE00
2026-06-18270CALL0 078.22TRUE00
2026-06-18280CALL0 074.45TRUE00
2026-06-182916.65CALL0 770.76TRUE00
2026-06-183015.5CALL1 2371.52TRUE15.50
2026-06-183112.8CALL0 272.54TRUE00
2026-06-183217.58CALL0 171.26TRUE00
2026-06-18339.86CALL0 171.02TRUE00
2026-06-18345.4CALL0 471.12TRUE00
2026-06-183514.18CALL0 168.76TRUE00
2026-06-183612.7CALL0 467.39TRUE00
2026-06-18370CALL0 068.44TRUE00
2026-06-18380CALL0 068.21TRUE00
2026-06-18396.3CALL0 168.25TRUE00
2026-06-184010.2CALL0 2568.1TRUE00
2026-06-18410CALL0 066.37TRUE00
2026-06-18428.5CALL0 172.2TRUE00
2026-06-18438.2CALL0 266.55FALSE00
2026-06-18447.8CALL0 665.72FALSE00
2026-06-18458.15CALL0 7571.26FALSE00
2026-06-18466.9CALL0 2265.75FALSE00
2026-06-18475.2CALL0 164.89FALSE00
2026-06-18486.57CALL0 765.17FALSE00
2026-06-18490CALL0 056.25FALSE00
2026-06-18505.3CALL0 5260.12FALSE00
2026-06-18553.1CALL0 2365.16FALSE00
2026-06-18602.5CALL0 2263.95FALSE00
2026-06-18652.2CALL0 7858.26FALSE00
2026-06-18701.59CALL0 9675.72FALSE00
2026-06-18151.25PUT0 1115.17FALSE00
2026-06-18190.4PUT0 1096.95FALSE00
2026-06-18200PUT0 0132.42FALSE00
2026-06-18210PUT0 0108.48FALSE00
2026-06-18221.88PUT0 2103.95FALSE00
2026-06-18230PUT0 0109.01FALSE00
2026-06-18241.5PUT0 185.71FALSE00
2026-06-18252.95PUT0 384.01FALSE00
2026-06-18261.2PUT0 182.17FALSE00
2026-06-18271.4PUT0 481.05FALSE00
2026-06-18281.55PUT0 278.97FALSE00
2026-06-18291.75PUT0 178.99FALSE00
2026-06-18302PUT0 459.76FALSE00
2026-06-18312.25PUT0 157.17FALSE00
2026-06-18321.8PUT1 558.08FALSE1.80
2026-06-18335.73PUT0 156.91FALSE00
2026-06-18345.2PUT0 157.97FALSE00
2026-06-18354.2PUT0 360.29FALSE00
2026-06-18363.8PUT0 257.8FALSE00
2026-06-18370PUT0 058.34FALSE00
2026-06-18384.8PUT0 359.07FALSE00
2026-06-18395.15PUT0 258.55FALSE00
2026-06-18405.2PUT0 1258.75FALSE00
2026-06-18410PUT0 055.97FALSE00
2026-06-18420PUT0 055.77FALSE00
2026-06-18436.77PUT0 157.55TRUE00
2026-06-18447.15PUT0 159.09TRUE00
2026-06-18450PUT0 058.67TRUE00
2026-06-18460PUT0 056.35TRUE00
2026-06-18470PUT0 061.19TRUE00
2026-06-18480PUT0 064.99TRUE00
2026-06-18490PUT0 063.9TRUE00
2026-06-18500PUT0 062.22TRUE00
2026-06-18550PUT0 062.17TRUE00
2026-06-18600PUT0 060.2TRUE00
2026-06-18650PUT0 062.33TRUE00
2026-06-18700PUT0 062.44TRUE00

Latest RIGL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$0.6924
Jun 13, 2022 7:59 PM EST200$0.6924
Jun 13, 2022 7:59 PM EST100$0.6924
Jun 13, 2022 7:59 PM EST500$0.6924
Jun 13, 2022 7:59 PM EST850$0.6921

Rigel Pharmaceuticals, Inc (RIGL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm
2019-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000021545719005836/0000215457-19-005836-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000031506619001306/0000315066-19-001306-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000031506620001146/0000315066-20-001146-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000083423720006820/0000834237-20-006820-index.htm
2020-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000083423720009960/0000834237-20-009960-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000090221919000369/0000902219-19-000369-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000090221920000160/0000902219-20-000160-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000093041319000568/0000930413-19-000568-index.htm
2019-04-09DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1034842/000104746919002080/0001047469-19-002080-index.htm
2020-04-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1034842/000104746920001990/0001047469-20-001990-index.htm
2020-05-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000104746920002759/0001047469-20-002759-index.htm
2020-08-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1034842/000104746920004389/0001047469-20-004389-index.htm
2018-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918034498/0001104659-18-034498-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918037232/0001104659-18-037232-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918050532/0001104659-18-050532-index.htm
2018-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465918050560/0001104659-18-050560-index.htm
2018-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918060459/0001104659-18-060459-index.htm
2018-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918064285/0001104659-18-064285-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918066323/0001104659-18-066323-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919001118/0001104659-19-001118-index.htm
2019-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919002845/0001104659-19-002845-index.htm
2019-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919005217/0001104659-19-005217-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919011582/0001104659-19-011582-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919017440/0001104659-19-017440-index.htm
2019-04-09DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000110465919020480/0001104659-19-020480-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919027507/0001104659-19-027507-index.htm
2019-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919029862/0001104659-19-029862-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919031798/0001104659-19-031798-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919044305/0001104659-19-044305-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465919044376/0001104659-19-044376-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919052388/0001104659-19-052388-index.htm
2019-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919055689/0001104659-19-055689-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919060054/0001104659-19-060054-index.htm
2019-11-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919065084/0001104659-19-065084-index.htm
2019-11-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919066635/0001104659-19-066635-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919073467/0001104659-19-073467-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920003446/0001104659-20-003446-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000110465920016449/0001104659-20-016449-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920026180/0001104659-20-026180-index.htm
2020-04-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000110465920041947/0001104659-20-041947-index.htm
2020-05-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920056879/0001104659-20-056879-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920062621/0001104659-20-062621-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920090262/0001104659-20-090262-index.htm
2020-08-04S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465920090388/0001104659-20-090388-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920113467/0001104659-20-113467-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920121776/0001104659-20-121776-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006680/0001179110-18-006680-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006681/0001179110-18-006681-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006682/0001179110-18-006682-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007148/0001179110-18-007148-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007149/0001179110-18-007149-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007150/0001179110-18-007150-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007151/0001179110-18-007151-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007152/0001179110-18-007152-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007153/0001179110-18-007153-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007154/0001179110-18-007154-index.htm
2018-06-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018008174/0001179110-18-008174-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018008176/0001179110-18-008176-index.htm
2018-07-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm
2018-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010636/0001179110-18-010636-index.htm
2018-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm
2018-08-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm
2018-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000931/0001179110-19-000931-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000932/0001179110-19-000932-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000933/0001179110-19-000933-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000934/0001179110-19-000934-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000935/0001179110-19-000935-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000936/0001179110-19-000936-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000938/0001179110-19-000938-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000939/0001179110-19-000939-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000940/0001179110-19-000940-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004205/0001179110-19-004205-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004206/0001179110-19-004206-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004207/0001179110-19-004207-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004208/0001179110-19-004208-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004209/0001179110-19-004209-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004210/0001179110-19-004210-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004211/0001179110-19-004211-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004212/0001179110-19-004212-index.htm
2019-04-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004736/0001179110-19-004736-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004740/0001179110-19-004740-index.htm
2019-05-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006694/0001179110-19-006694-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006698/0001179110-19-006698-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006699/0001179110-19-006699-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006700/0001179110-19-006700-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006701/0001179110-19-006701-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006702/0001179110-19-006702-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006703/0001179110-19-006703-index.htm
2019-11-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011701/0001179110-19-011701-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011937/0001179110-19-011937-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011938/0001179110-19-011938-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011940/0001179110-19-011940-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011942/0001179110-19-011942-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011944/0001179110-19-011944-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011946/0001179110-19-011946-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011948/0001179110-19-011948-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001348/0001179110-20-001348-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001349/0001179110-20-001349-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001350/0001179110-20-001350-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001351/0001179110-20-001351-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006129/0001179110-20-006129-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006130/0001179110-20-006130-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006131/0001179110-20-006131-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006132/0001179110-20-006132-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006133/0001179110-20-006133-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006134/0001179110-20-006134-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006135/0001179110-20-006135-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm
2020-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020009204/0001179110-20-009204-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020009207/0001179110-20-009207-index.htm
2019-11-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000131924419000084/0001319244-19-000084-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000131924420000054/0001319244-20-000054-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837018006758/0001558370-18-006758-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837018008624/0001558370-18-008624-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1034842/000155837019001310/0001558370-19-001310-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019004244/0001558370-19-004244-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019007232/0001558370-19-007232-index.htm
2019-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019009974/0001558370-19-009974-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1034842/000155837020001624/0001558370-20-001624-index.htm
2020-05-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020005179/0001558370-20-005179-index.htm
2020-08-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020009154/0001558370-20-009154-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020012838/0001558370-20-012838-index.htm
2019-03-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999719001548/9999999997-19-001548-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000137/9999999997-20-000137-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000138/9999999997-20-000138-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000139/9999999997-20-000139-index.htm
2020-02-05SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000517/9999999997-20-000517-index.htm
2020-02-18SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000741/9999999997-20-000741-index.htm
2020-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720002114/9999999997-20-002114-index.htm
2020-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720002115/9999999997-20-002115-index.htm

Rigel Pharmaceuticals, Inc (RIGL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rigel Pharmaceuticals, Inc (RIGL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 31%
Institutional Ownership: 8526%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-07-02Anne-Marie DuliegeEVP & Chief Medical OfficerSell5,000.002.7913,932.000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm
2018-09-04Anne-Marie DuliegeEVP & Chief Medical OfficerSell16,500.003.5157,860.550.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerSell115,500.003.50404,250.000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-08-23Eldon C. III MayerEVP & Chief Commercial OfficerBuy100,000.002.82282,320.00115,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerBuy115,500.002.54293,370.00115,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-09-04Anne-Marie DuliegeEVP & Chief Medical OfficerBuy16,500.002.5441,910.0016,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-10Eldon C. III MayerEVP & Chief Commercial OfficerBuy50,000.003.28164,210.00165,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-08-17RAUL R RODRIGUEZCEO, PresidentBuy114,000.002.63300,002.40173,519.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm
2018-09-11Eldon C. III MayerEVP & Chief Commercial OfficerBuy50,000.003.23161,340.00215,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerBuy37,500.002.1179,125.0037,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2019-05-22Dean L SchornoEVP &Chief Financial OfficerBuy46,726.002.1399,573.1146,726.00https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2019-05-22Dean L SchornoEVP &Chief Financial OfficerBuy3,274.002.136,971.0050,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2018-10-12Nelson CabatuanPrincipal Accounting OfficerSell10,000.003.1231,200.0058.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm